Published by
@ShahidNShah
@ShahidNShah
5th Gene Therapy for Ophthalmic Disorders Summit is sheduled on 10-12 September 2024 in Boston, MA. Ophthalmic drug developers are unlocking the full potential of gene therapy. Crucial lessons learnt from both clinical successes and failures, coupled with recent improvements in development and delivery, means that the space is poised to capitalize on the significant potential of the eye as a target for genetic medicine approaches.Understand the crucial role of endpoint selection to clearly demonstrate product efficacy to the FDA & EMA. Understand the risk-benefit profiles of different ocular administration routes including intravitreal, subretinal, and suprachoroidal delivery to choose the best option for your specific indication.
[Read on genetherapy-ophthalmology.com](https://genetherapy-ophthalmology.com/take-part/register/)
Continue reading at genetherapy-ophthalmology.com
September 11 to September 16, 2024
Svenska Mässan, Mässans Gata/Korsvägen, Göteborg, Västra Götalands län, 412 94, Sweden
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Media LLC. All Rights Reserved.
Built on Sep 6, 2024 at 12:08pm